Lumigen Biotech is a Maryland-based oncology company developing NOVVA™, an antibody-guided nanocomplex platform designed to deliver high concentrations of chemotherapy into tumors that existing modalities, including ADCs, cannot reach. Our lead program, LUM-001, targets Fn14-positive cancers characterized by dense stroma, infiltrative growth, and brain involvement.